New Jersey Federal Judge Enjoins Sales Of Generic Levothyroxine Formulation

(September 21, 2016, 1:16 PM EDT) -- TRENTON, N.J. — Although denying a plaintiff’s request to dismiss counterclaims of inequitable conduct, a New Jersey federal judge on Sept. 20 nonetheless granted the plaintiff a preliminary injunction in a patent dispute over injectable lyophilized levothyroxine (Fresenius Kabi USA LLC v. Fera Pharmaceuticals LLC, et al., No. 15-3654, D. N.J.; 2016 U.S. Dist. LEXIS 128126).

(Decision available. Document #16-161003-006Z.)

According to U.S. Judge Kevin McNulty of the District of New Jersey, plaintiff Fresenius Kabi USA LLC enjoys a reasonable likelihood of success on the merits...
To view the full article, register now.